In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Hold rating on Valeant Pharma (NYSE: VRX), with a price target of $20. The company’s shares closed yesterday at $20.25.
Selvaraju commented:
“Exchange NYSE Value (M) $31,421.0 Market Cap (M) $7,064 Public Market Float (M) 329.9 Shares Outstanding (M) 348.8 3 Interest (M) 40.90 Cash (M) $909.0 Total Debt (M) $25,266.0 Year – (0.25) FY 6.86 (7.48) (1.32) FY P/E 3.0x NM NM Year – 2,290.0 FY 8,724.0 8,325.0 8,810.0 30 25 20 15 10 0 Vol.”
According to TipRanks.com, Selvaraju has 0 stars on 0-5 star ranking scale with an average return of -4.5% and a 38.2% success rate. Selvaraju covers the Healthcare sector, focusing on stocks such as IntelliPharmaCeutics International, Biospecifics Technologies Corp, and EyePoint Pharmaceuticals Inc.
Currently, the analyst consensus on Valeant Pharma is Hold and the average price target is $18.14, representing a -10.4% downside.
In a report issued on May 2, RBC Capital also reiterated a Hold rating on the stock with a $18 price target.
See today’s analyst top recommended stocks >>
Based on Valeant Pharma’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $2 billion and GAAP net loss of $2.69 billion. In comparison, last year the company earned revenue of $2.11 billion and had a net profit of $628 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Valeant Pharmaceuticals International, Inc. engages in the development, manufacture, and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: The Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products.
Read More on VRX:
